Quick Answer
Monopar Therapeutics reported Net Income Loss of -$13.72 million for the year ending 2025.
- Monopar Therapeutics showed an increase of +12.0% in Net Income Loss from 2024 to 2025.
- This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$372.9 thousand | Q2 2017: -$591.4 thousand | Q3 2017: -$14.88 million | Q1 2018: -$876.3 thousand | Q2 2018: -$640.2 thousand | Q3 2018: -$640.2 thousand | Q4 2018: -$890.5 thousand | Q1 2019: -$1.38 million | Q2 2019: -$905.7 thousand | Q3 2019: -$736.1 thousand | Q1 2020: -$1.09 million | Q2 2020: -$1.45 million | Q3 2020: -$1.64 million | Q1 2021: -$1.88 million | Q2 2021: -$2.08 million | Q3 2021: -$2.46 million | Q1 2022: -$2.46 million | Q2 2022: -$2.76 million | Q3 2022: -$2.40 million | Q1 2023: -$2.43 million | Q2 2023: -$2.20 million | Q3 2023: -$1.95 million | Q1 2024: -$1.64 million | Q2 2024: -$1.72 million | Q3 2024: -$1.30 million | Q1 2025: -$2.62 million | Q2 2025: -$2.45 million | Q3 2025: -$3.44 million.
- Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Net Income Loss has declined by 1,057.0%.
- Historical annual values: Fiscal year 2025: -$13.72 million | Fiscal year 2024: -$15.59 million | Fiscal year 2023: -$8.40 million | Fiscal year 2022: -$10.52 million | Fiscal year 2021: -$9.10 million | Fiscal year 2020: -$6.30 million | Fiscal year 2019: -$4.22 million | Fiscal year 2018: -$3.23 million | Fiscal year 2017: -$16.55 million | Fiscal year 2016: -$1.19 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: